Should We Consider Screening Spirometry in Individuals Who Are “Asymptomatic”?

Spyridon Fortis, M.D.¹,²

¹Veterans Rural Health Resource Center-Iowa City, Veterans Affairs Office of Rural Health and Center for Access and Delivery Research and Evaluation (CADRE) at the Iowa City Veterans Affairs Healthcare System, Iowa City, Iowa; and ²Department of Internal Medicine, Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa

ORCID ID: 0000-0001-7807-6740 (S.F.).

Chronic obstructive pulmonary disease (COPD) diagnosis requires an airflow obstruction (AFO) in spirometry according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines (1). Spirometric testing is typically reserved for individuals with respiratory symptoms. The USPSTF (U.S. Preventive Services Task Force) recommends against screening individuals who are asymptomatic with the rationale that early diagnosis does not modify the disease course and does not improve patient outcomes (2). Nevertheless, the USPSTF did not find any significant harm from screening besides wasting resources and acknowledged that further studies are needed to assess screening spirometry in high-risk individuals, including those with smoking exposure. This is on par with the GOLD guidelines, which recommend spirometry in those with respiratory symptoms and other risk factors such as more than 20 pack-years of smoking exposure (1).

In the current issue of *AnnalsATS*, Bhatt and colleagues (pp. 1294–1304) demonstrated the importance of detecting AFO in individuals who are asymptomatic (3). Using harmonized data from nine U.S. cohort studies, they analyzed data of 14,024 adults without respiratory symptoms or prior respiratory disease that had spirometric data. In a racially and ethnically diverse sample with 54% females, the prevalence of AFO in individuals who are asymptomatic (SAO) was 13.2%. There were 1,325 COPD-related hospitalizations and 131 COPD-related deaths over a median follow-up time of 16 years. Individuals with SAO had 3 to 5 times higher rates of COPD-related hospitalizations or deaths independent of their smoking history. The authors went one step further and created a probability scoring system to predict SAO using simple variables: age, sex, race, accumulated smoking exposure, current smoking status (current or former smoking), and body mass index. Their scoring system showed a very good discriminative ability to predict SAO with an area under the curve in the receiver operating characteristic curve of 0.81 (95% confidence interval, 0.8–0.82). The 15% probability threshold was found to have the best discriminative ability. Using that threshold, one individual with SAO can be diagnosed for every 3.2 individuals who undergo spirometry.

The study was well conducted and seems free of selection bias as it used data from nine large prospective U.S. cohorts. There may be a misclassification in SAO as spirometries were categorized as AFO or normal. Preserved ratio impaired spirometry was classified as normal while it is well established that it is associated with worse outcomes relative to normal spirometry (4). In addition, a fixed forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) threshold was used (below 0.7), which may overdiagnose AFO in elderly and underdiagnose AFO in young individuals. Nevertheless, a prior study using data from the same cohorts showed that the discriminative ability of FEV₁/FVC less than 0.7 for COPD-related hospitalization and mortality was superior to that of the lower limit of normal (5). Prebronchodilator values were used to diagnose SAO instead of postbronchodilator spirometry, which is recommended by the GOLD guidelines (1). Although postbronchodilator FEV₁/FVC less than 0.7 is a better predictor for respiratory symptoms, chest computed tomography features, and mortality than prebronchodilator FEV₁/FVC less than 0.7, their discriminative ability are marginally different (6).

Apart from the minor potential aforementioned limitations, the study has many strengths. The probability scoring system was validated in an external cohort and showed similar accuracy in the training dataset. Several sensitivity analyses were conducted, demonstrating the robustness of their findings. Most important, the variables used in the probability scoring system were clinically relevant and can be easily extracted using electronic health records. Moreover, the study findings are generalizable because the data were derived from several general population cohorts.

Expanding spirometry testing for COPD has been the research focus of several prior investigations (7). COPD underdiagnosis has been reported to be as high as 81.4% (7). In a sample of individuals from the general population that were at least 40 years old with at least 10 pack-years of smoking exposure and after excluding those with a history of asthma, Colak and
colleagues showed that 11% of these individuals had AFO (8). Of those participants with AFO, 78% did not carry a COPD diagnosis. Thirty percent of those with no AFO and prior diagnosis of COPD were asymptomatic. Despite the absence of respiratory symptoms, those individuals had a higher risk for exacerbations, pneumonia, and all-cause mortality than those with no COPD. A study using electronic health record data of patients with COPD in the United Kingdom showed that 38% of the patients had only mild dyspnea, defined by the MRC (Medical Research Council) dyspnea scale as one, which corresponds to shortness of breath when hurrying or walking up a slight hill, while 44% of those had moderate dyspnea (MRC dyspnea scale of two), which corresponds to walking slower than peers (9). Even among patients with FEV₁% predicted less than 35%, more than 20% had MRC of one or two. In patients with FEV₁% predicted between 35% and 50%, more than 40% had MRC of one or two. Similarly, the PLATINO (Latin American Project for Research in Pulmonary Obstruction) study data showed that half of the patients with COPD and FEV₁% predicted between 50% and 80%, and one-third of those with FEV₁% predicted less than 50% reported good to excellent health status (10).

Screening spirometry in individuals who are asymptomatic with risk factors like age above 40 years and a history of smoking exposure makes sense. An easy target population is the participants in the lung cancer screening program because they have a significant smoking history (accumulating smoking exposure of 20 or more pack-years) and must be above 50 years of age to qualify for screening. In a lung cancer screening cohort, 34% of the participants had AFO, with 87% of those not having a previous diagnosis of obstructive lung disease (11). Participants in lung cancer screening programs are not only at high risk, but they are also willing to undergo preventive diagnostics tests. The probability scoring system created by Bhatt and colleagues gives the opportunity to increase spirometric testing beyond the lung cancer screening program. The commonly available variables used for the scoring system allow its application in electronic health records via an automated fashion with minimal cost. Such an application can alert the user that the patient is at risk for COPD, thus encouraging screening spirometry. Whether early identification of COPD in individuals who are asymptomatic improves outcomes is unknown. Nevertheless, early diagnosis may lead to early treatment and improved outcomes. Early treatment improves respiratory symptoms and reduces exacerbations and, therefore, may reduce rapid lung function decline and mortality (12).

Conclusions
The burden of SAO in the U.S. population is high. The probability scoring system provided by Bhatt and colleagues in the current issue of AnnalsATS can serve as a tool to identify high-risk individuals who are asymptomatic for COPD that may benefit from screening spirometry. Future research should investigate whether screening spirometry in these individuals improves their outcomes.

Author disclosures are available with the text of this article at www.atsjournals.org.

References
1. Global strategy for diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease [accessed 2022 Apr 28]. Available from https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMv.pdf.
2. Siu AL, Bibbins-Domingo K, Grossman DC, Davidson KW, Epling JW Jr, Garcia FA, et al.; US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: U.S. Preventive Services Task Force recommendation statement. JAMA 2016;315:1372–1377.
3. Bhatt SP, Balte PP, Schwartz JE, Jaeger BC, Cassano PA, Chaves PH, et al. Pooled cohort probability score for subclinical airflow obstruction. Ann Am Thorac Soc 2022;19:1294–1304.
4. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, et al.; COPDGene Investigators. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med 2018;198:1397–1405.
5. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR Jr, et al. Discriminative accuracy of FEV₁/FVC thresholds for COPD-related hospitalization and mortality. JAMA 2019;321:2438–2447.
6. Fortis S, Eberlein M, Georgopoulos D, Comellas AP. Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes. BMJ Open Respir Res 2017;4:e000213.
7. Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, et al. Underdiagnosis and overdagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;198:1130–1139.
8. Colak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med 2017;5:426–434.
9. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One 2014;9:e85540.
10. Jones RC, Price D, Ryan D, Sim S, Ej J, von Zügenweidt J, Mascarenhas L, et al.; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the United Kingdom: a retrospective study of a clinical cohort. Lancet Respir Med 2014;2:267–276.
11. de-Torres JP, Wisnivesky JP, Bastarrick G, Wilson DO, Celli BR, Zulueta JJ. The prevalence of obstructive lung disease in a lung cancer screening cohort: analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort. Ann Am Thorac Soc 2019;16:641–644.
12. Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, et al. CONQUEST quality standards: for the collaboration on quality improvement initiative for achieving excellence in standards of COPD care. Int J Chron Obstruct Pulmon Dis 2021;16:2301–2322.